The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the importance of clinical characterization of children with monosymptomatic nocturnal enuresis (MNE) in order to improve treatment efficacy.

The hypothesis is that clinical characterization by measurement of nocturnal urine production and maximal voided volumes in children with MNE and subsequent treatment tailoring improves the response to first-line treatment approach.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborators: First Affiliated Hospital of Zhengzhou University, China; University Clinical Centre in Gdansk, Poland; University Ghent
• Treatments: Deamino Arginine Vasopressin

Criteria

Inclusion Criteria:

• Age 6-14 years.

• Three or more wet nights per week regarding the home registrations.

Exclusion Criteria:

• Ongoing constipation and/or faecal incontinence.

• Daytime symptoms such as urgency, frequency or incontinence.

• Recurrent urinary tract infections.

• Anamnestic, clinical or laboratory findings that can be related to diseases or conditions that might affect the parameters investigated.

• Neurological and/or known clinically significant anatomical abnormalities of the urinary tract.

• Former operations in the urinary tract.

• Prior or ongoing treatment with alarm, desmopressin or anticholinergics.

• Ongoing medication that may interfere with the parameters tested.

• Pregnant or lactating girl.

• Contra-indications for the use of desmopressin: habitual or psychogenic polydipsia, use of diuretics, renal insufficiency, hyponatremia or SIADH.

• Hypersensitivity / allergy to substances in the tablets.